Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632630 | 1.00 | TSHR (0.62) | TSHRALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL25326335 | 0.92 | TSHR (0.54) | TSHRALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL334074 | 0.86 | GAA (0.61) | TSHRALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL14438957 | 0.86 | ALDH1A1 (0.53) | TSHRALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL2003361 | 0.86 | ALDH1A1 (0.66) | TSHRALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL10229485 | 0.86 | ALDH1A1 (0.53) | TSHRALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL14216112 | 0.85 | NPC1 (0.65) | TSHRALDH1A1SIGMAR1LMNAKMT2A | |
| SCHEMBL2982711 | 0.84 | ALDH1A1 (0.51) | TSHRALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL377583 | 0.84 | CYP4F2 (0.53) | TSHRALDH1A1GAAGFERCYP4F2 | |
| SCHEMBL2434505 | 0.84 | ALDH1A1 (0.64) | TSHRALDH1A1GAAGFERCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12582719-B2 | Chimeric compounds and methods of managing neurological disorders or conditions | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| CN-118702710-A | Method for synthesizing organoboron compound by visible light catalysis | 常州大学 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024098361-A1 | ARTIFICIAL NUCLEIC ACID MOLECULE | 斯微(上海)生物科技股份有限公司 | 2024-05-16 | — | — | WO | disclosed |
| CN-115417738-B | Photo-induced alpha-hydrofluorination method for diazoaryl ester compound | 哈尔滨工业大学（深圳） | 2023-10-03 | — | — | CN | disclosed |
| US-20230263742-A1 | A LIPID | Stemirna Therapeutics Co., Ltd. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-4293462-A | Process for the manufacture of enol derivatives, and intermediates | CIBA-GEIGY CORPORATION (US) | 1981-10-06 | — | — | US | disclosed |
| US-4269977-A | Process for the manufacture of 8-oxo-5-thia-1-azabicyclo [4,2,0]oct-2-ene or 3-ene compounds | CIBA-GEIGY CORPORATION (US) | 1981-05-26 | — | — | US | disclosed |
| US-4256739-A | 7β-Amino-3-thio-3-cephem-4-carboxylic acid compounds, and antibacterial compositions and methods using them | CIBA-GEIGY CORPORATION (US) | 1981-03-17 | — | — | US | disclosed |
| US-4255328-A | CEPHALOSPORINS | CIBA-GEIGY CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |
| US-4172832-A | Mercaptoalcohols and process for their manufacture | CIBA-GEIGY CORPORATION (US) | 1979-10-30 | — | — | US | disclosed |
| US-4147864-A | Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| US-4110533-A | PROCESS FOR THE MANUFACTURE OF ENOL DERIVATIVES | CIBA-GEIGY CORPORATION (US) | 1978-08-29 | — | — | US | disclosed |
| US-4013650-A | PROCESS FOR THE MANUFACTURE OF 3-METHYLENE-CEPHAM COMPOUNDS | CIBA-GEIGY CORPORATION (US) | 1977-03-22 | — | — | US | disclosed |
| US-3989695-A | 7β-Amino-cepham-3-ol-4-carboxylic acid compounds | CIBA-GEIGY CORPORATION (US) | 1976-11-02 | — | — | US | disclosed |
| US-3932465-A | ANTIBIOTIC | CIBA-GEIGY CORPORATION (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263742-A1 | A LIPID | CETP, PLIN1, AUP1 | TSHR 2301/4885ALDH1A1 1643/4885GAA 2191/4885 |
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | TSHR 1531/4885ALDH1A1 193/4885GAA 839/4885 |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | TSHR 3787/4885ALDH1A1 3865/4885GAA 1558/4885 |
| US-12582719-B2 | Chimeric compounds and methods of managing neurological disorders or conditions | SLC6A4, HTR4, HTR1A | TSHR 206/4885ALDH1A1 637/4885GAA 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.